TRCT
ABMD

Tower Research Capital (TRC)’s Abiomed Inc ABMD Stock Holding History

Tower Research Capital (TRC)’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,397
Closed -$1.57M – 6765
2022
Q3 		$1.57M Buy
6,397
+1,613
+34% +$436K 0.03% 515
2022
Q2 		$1.19M Sell
4,784
-6,280
-57% -$1.69M 0.03% 597
2022
Q1 		$3.67M Buy
11,064
+6,134
+124% +$1.89M 0.04% 390
2021
Q4 		$1.77M Buy
4,930
+2,962
+151% +$1M 0.03% 466
2021
Q3 		$641K Sell
1,968
-2,585
-57% -$876K 0.02% 815
2021
Q2 		$1.42M Buy
4,553
+1,710
+60% +$525K 0.04% 447
2021
Q1 		$906K Buy
2,843
+2,178
+328% +$697K 0.02% 830
2020
Q4 		$216K Sell
665
-98
-13% -$27.1K 0.01% 1643
2020
Q3 		$211K Sell
763
-3,933
-84% -$1.13M ﹤0.01% 2531
2020
Q2 		$1.14M Buy
4,696
+4,006
+581% +$804K 0.05% 444
2020
Q1 		$100K Buy
690
+530
+331% +$88K 0.01% 994
2019
Q4 		$27K Sell
160
-2,427
-94% -$450K ﹤0.01% 1747
2019
Q3 		$460K Buy
+2,587
New +$559K 0.03% 596
2019
Q2 		– Sell
-1,268
Closed -$362K – 4525
2019
Q1 		$362K Sell
1,268
-891
-41% -$296K 0.02% 813
2018
Q4 		$701K Buy
2,159
+2,078
+2,565% +$722K 0.05% 339
2018
Q3 		$36K Sell
81
-2,389
-97% -$942K ﹤0.01% 1971
2018
Q2 		$1.01M Sell
2,470
-184
-7% -$66.7K 0.06% 349
2018
Q1 		$773K Buy
2,654
+2,422
+1,044% +$614K 0.07% 282
2017
Q4 		$44K Buy
232
+220
+1,833% +$41.1K 0.01% 1433
2017
Q3 		$2K Buy
+12
New +$1.81K ﹤0.01% 3609
2017
Q2 		– Sell
-14
Closed -$1.88K – 3661
2017
Q1 		$2K Sell
14
-260
-95% -$30.1K ﹤0.01% 2698
2016
Q4 		$31K Sell
274
-588
-68% -$68.1K ﹤0.01% 1771
2016
Q3 		$110K Sell
862
-2,299
-73% -$275K 0.01% 768
2016
Q2 		$345K Buy
3,161
+3,057
+2,939% +$304K 0.03% 390
2016
Q1 		$10K Buy
+104
New +$8.78K ﹤0.01% 1998
2015
Q4 		– Sell
-947
Closed -$88K – 5237
2015
Q3 		$88K Buy
947
+805
+567% +$70.9K 0.01% 634
2015
Q2 		$9K Sell
142
-879
-86% -$58.4K ﹤0.01% 2833
2015
Q1 		$73K Buy
+1,021
New +$55.4K 0.01% 1171
2014
Q3 		– Sell
-510
Closed -$13K – 5026
2014
Q2 		$13K Sell
510
-923
-64% -$21.5K ﹤0.01% 2167
2014
Q1 		$37K Buy
+1,433
New +$39.6K ﹤0.01% 1326
2013
Q4 		– Sell
-3,100
Closed -$59K – 5034
2013
Q3 		$59K Sell
3,100
-766
-20% -$17.5K 0.01% 1768
2013
Q2 		$83K Buy
+3,866
New +$77.7K 0.01% 610

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $484M AUM 15.17% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Tower Research Capital (TRC)'s ABMD Position: Q4 2022 in Review

Tower Research Capital (TRC) sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 6,397 shares — an estimated $1.57M sold.

Tower Research Capital (TRC) first reported a position in ABMD in Q2 2013 and held it in 32 quarters. The position peaked at $3.67M in Q1 2022. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Tower Research Capital (TRC) reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 6,397 Abiomed Inc shares in Q4 2022, an estimated $1.57M.
  • Tower Research Capital (TRC) first reported a position in Abiomed Inc in Q2 2013 and held it in 32 quarters.
  • Tower Research Capital (TRC)'s Abiomed Inc position peaked at $3.67M in Q1 2022.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2022, filed 10 Feb 2023.